Fig. 2.
VEGF blocking and prolongation of survivals (A) At day 14 after treatment with MF1 and DC101, a representative mouse of each group was photographed. Arrows point to nose/mouth and paws. Asterisks mark the abdomens of mice. (B) Tumor volumes were measured at the indicated times to determine tumor growth rates. (D) The percentage of survival animals in each group is presented during a 15-day-treatment course. (E and F) After killing of animals on day 15 after treatment, livers and spleens were weighed and mean values are presented. (C) At the same time point, liver, spleen, adrenal gland, and BM of buffer-treated, MF1-treated, and DC101-treated mice (n = 8/group) were stained with H&E (top four sets of images). PA = portal area; RP = red pulp; WP = white pulp; Cx = cortex; and M = medulla. Vascular networks in tumors and livers were revealed by staining with a CD31 antibody (bottom two sets of images). (Scal bar, 50 μm.) (G) CD31 positive signals were quantified in tumor tissues. (H) VEGF tumors were allowed to grow into sizes of 0.8 cm3, followed by treatment with bevacizumab for 10 days. The mouth/nose and paws from a representative mouse of each group was photographed. (I-K) Tumor growth rates, liver weight, and spleen weight were measured. (L) The percentages of survival animals in bevacizumab- versus buffer-treated groups were presented during a 19-day experimental period.